Skip to Content

Join the 'Chronic Lymphocytic Leukemia (CLL)' group to help and get support from people like you.

Chronic Lymphocytic Leukemia (CLL) News

Related terms: Cancer, Chronic Lymphocytic Leukemia, Leukemia, Chronic Lymphocytic, CLL

FDA Approves Rituxan Hycela (rituximab and hyaluronidase human) for Subcutaneous Injection in Certain Blood Cancers

Posted 26 Jun 2017 by

South San Francisco, CA – June 22, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory ...

Gleevec Keeps a Leukemia in Check for More Than a Decade: Study

Posted 9 Mar 2017 by

WEDNESDAY, March 8, 2017 – The cancer drug Gleevec appears to keep chronic myeloid leukemia at bay a decade into treatment – with no signs of additional safety risks, a new study finds. Gleevec – known generically as imatinib – was hailed as a "wonder drug" when it was introduced in 2001 for treating chronic myeloid leukemia (CML). CML is a type of blood cancer that strikes about 5,000 ...

Gene Therapy Helps 2 Babies Fight Type of Leukemia

Posted 25 Jan 2017 by

WEDNESDAY, Jan. 25, 2017 – Two infants with an advanced form of leukemia are in remission after treatment with genetically tweaked immune system cells, British researchers report. Both babies had run out of treatment options for their cancer, known as B-cell acute lymphoblastic leukemia, or ALL. But, after treatment with genetically altered T-cells – a type of immune system cell – both went ...

Genmab Announces U.S. FDA Approval of Arzerra (ofatumumab) in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL

Posted 1 Sep 2016 by

Copenhagen, Denmark; August 31, 2016 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the use of ofatumumab (Arzerra®) in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). The application, wh ...

Venclexta Approved for Specific Genetic Blood Cancer

Posted 12 Apr 2016 by

MONDAY, April 11, 2016 – Venclexta (venetoclax) has been approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL) characterized by a specific chromosomal abnormality called the 17p deletion. People with this abnormality lack a portion of a chromosome that thwarts cancer growth, the agency said in a news release. It occurs in 10 percent to 20 percent of people ...

FDA Approves Venclexta (venetoclax) for Chronic Lymphocytic Leukemia with 17p Deletion

Posted 12 Apr 2016 by

April 11, 2016 – The U.S. Food and Drug Administration today approved Venclexta (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. Venclexta is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer ...

FDA Alerts Healthcare Professionals About Clinical Trials with Zydelig (idelalisib) in Combination with other Cancer Medicines

Posted 16 Mar 2016 by

March 14, 2016 – The U.S. Food and Drug Administration is alerting health care professionals about reports of an increased rate of adverse events, including deaths, in clinical trials with the cancer medicine Zydelig (idelalisib) in combination with other cancer medicines. Gilead Sciences, Inc. has confirmed that they are stopping six clinical trials in patients with chronic lymphocytic ...

FDA Approves Imbruvica (ibrutinib) for the First-Line Treatment of Chronic Lymphocytic Leukemia

Posted 8 Mar 2016 by

NORTH CHICAGO, Ill., March 4, 2016 /PRNewswire/ – AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).1 The approval is based on data from the randomized, multi-center, open-label Phase 3 RESONATE™-2 (PCYC-1115) trial, w ...

New Immune Therapy Achieves Complete Remission in Blood Cancer Patients

Posted 16 Feb 2016 by

A new therapy that uses a person's immune system to attack tumors led to complete remission in terminally ill blood cancer patients, according to researchers. In a clinical trial, symptoms vanished in 94 percent of leukemia patients who received the treatment. The response rate was more than 80 percent in patients with other blood cancers, and half achieved total remission, CNBC reported. The ...

Genmab Announces U.S. FDA Approval of Arzerra (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL

Posted 20 Jan 2016 by

Copenhagen, Denmark; January 19, 2016 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the use of Arzerra (ofatumumab) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic l ...

Antibody May Lower Rejection Rates After Stem Cell Transplant in Leukemia Patients

Posted 7 Jan 2016 by

WEDNESDAY, Jan. 6, 2016 – People with acute leukemia who were given antibody therapy before a stem cell transplant fared better than those who didn't receive the treatment, a small study found. Stem cell transplantation allows doctors to give higher doses of cancer-killing chemotherapy, according to the American Cancer Society. However, the odds of the body rejecting the transplanted stem cells ...

End-of-Life Talk Often Comes Too Late for Blood Cancer Patients

Posted 21 Dec 2015 by

MONDAY, Dec. 21, 2015 – Many doctors wait too long to have end-of-life discussions with blood cancer patients, a new study finds. Researchers analyzed surveys completed by 349 blood cancer specialists, and found that 56 percent said end-of-life discussions with patients happen too late. Nearly 43 percent said they had their first end-of-life discussions with patients at less-than-ideal times, ...

Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of Bendeka (bendamustine hydrochloride) Injection

Posted 10 Dec 2015 by

JERUSALEM & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Dec. 8, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announce that the U.S. Food and Drug Administration (FDA) has approved Bendeka, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. Bendeka is approved ...

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is ...

Immune Cell Therapy Shows Promise Against Deadly Blood Cancer

Posted 2 Sep 2015 by

WEDNESDAY, Sept. 2, 2015 – An experimental therapy for chronic lymphocytic leukemia (CLL) that uses a patient's own immune cells may cure some patients and prolong survival in others with the blood cancer, researchers report. The process of creating the therapy, called CTL019, begins with a patient's own T cells, which are a type of white blood cell essential for an immune response. The cells ...

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Infection Prophylaxis, Chronic Lymphocytic Leukemia, Leukemia

Related Drug Support Groups

Rituxan, rituximab, Imbruvica, Cytoxan, bendamustine, cyclophosphamide, ibrutinib, Treanda, Leukeran, view more... Carimune, immune globulin intravenous, Fludara, Neosar, alemtuzumab, Octagam, Carimune NF, chlorambucil, Bendeka, Venclexta, Arzerra, Sandoglobulin, Rituxan Hycela, obinutuzumab, idelalisib, venetoclax, Campath, Gamimune, fludarabine, ofatumumab, Zydelig, Gazyva, Gammar IV, Gammaplex, Oforta, Cytoxan Lyophilized, Gammagard S / D, Flebogamma, Iveegam En, Panglobulin, Gamimune N 10%, Gamimune N 5%, Polygam S / D, Gammar-P IV, Venoglobulin-S 10%, Venoglobulin-S 5%, Panglobulin NF, hyaluronidase / rituximab